IL6 and congenital rubella syndrome: The management of CRS is guided by the severity and duration of symptoms and ranges from supportive measures with antipyretics to anti-IL6 directed therapy with tocilizumab and corticosteroids, and severe cases may require anti-TNF therapy and organ support in the intensive care unit (Table 3) [17,20].